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Abstract
Background: Although the release of cardiac biomarkers after percutaneous (PCI) or surgical revascularization
(CABG) is common, its prognostic significance is not known. Questions remain about the mechanisms and degree
of correlation between the release, the volume of myocardial tissue loss, and the long-term significance.
Delayed-enhancement of cardiac magnetic resonance (CMR) consistently quantifies areas of irreversible myocardial
injury. To investigate the quantitative relationship between irreversible injury and cardiac biomarkers, we will
evaluate the extent of irreversible injury in patients undergoing PCI and CABG and relate it to postprocedural
modifications in cardiac biomarkers and long-term prognosis.
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Methods/Design: The study will include 150 patients with multivessel coronary artery disease (CAD) with left
ventricle ejection fraction (LVEF) and a formal indication for CABG; 50 patients will undergo CABG with
cardiopulmonary bypass (CPB); 50 patients with the same arterial and ventricular condition indicated for myocardial
revascularization will undergo CABG without CPB; and another 50 patients with CAD and preserved ventricular
function will undergo PCI using stents. All patients will undergo CMR before and after surgery or PCI. We will also
evaluate the release of cardiac markers of necrosis immediately before and after each procedure. Primary outcome
considered is overall death in a 5-year follow-up. Secondary outcomes are levels of CK-MB isoenzyme and
I-Troponin in association with presence of myocardial fibrosis and systolic left ventricle dysfunction assessed by CMR.
Discussion: The MASS-V Trial aims to establish reliable values for parameters of enzyme markers of myocardial
necrosis in the absence of manifest myocardial infarction after mechanical interventions. The establishments of these
indices have diagnostic value and clinical prognosis and therefore require relevant and different therapeutic
measures. In daily practice, the inappropriate use of these necrosis markers has led to misdiagnosis and therefore
wrong treatment. The appearance of a more sensitive tool such as CMR provides an unprecedented diagnostic
accuracy of myocardial damage when correlated with necrosis enzyme markers. We aim to correlate laboratory data
with imaging, thereby establishing more refined data on the presence or absence of irreversible myocardial injury
after the procedure, either percutaneous or surgical, and this, with or without the use of cardiopulmonary bypass.
Keywords: Cardiopulmonary bypass, Necrosis markers, Myocardial infarction, PCI, CABG
Background
The release of creatine phosphokinase enzymes (CPK),
CK-MB isoenzyme (CK-MB), cardiac troponin, or both, in
the absence of ECG waves indicating necrosis during per-
cutaneous or surgical procedures has occurred in 10 to
35 % of cardiac patients. These indices are considered
diagnostic for acute myocardial infarction (AMI) [1,2].
Such results are important, because they are similar to
those found during spontaneous cardiac events in the
population of patients with coronary artery disease (CAD)
[3]. The release of enzyme markers of myocardial cells
allows the diagnosis of AMI, when the levels of CK-MB
or troponin are elevated up to 3 times above the estab-
lished standard for percutaneous interventions (PCI)
and up to 5 times for surgical revascularization (CABG)
even in the absence of electrocardiographic changes or
clinical symptoms [4,5]. On the other hand, these indi-
ces, considered indicative of AMI, have prognostic value
according to the severity of the patient and the proced-
ure performed. In this scenario, the prognosis for this
event can be associated with the degree of elevation of
biomarkers released and with the type of intervention
applied. Also included in the prognosis of the condition
are the number of arteries involved, the degree of arter-
ial and ventricular impairment, and the type of inter-
vention performed.
However, both invasive and noninvasive investigations
during the period after the intervention have limitations
related to the poor the sensitivity and specificity of the
ECG and biomarkers. Although cardiac-specific biomar-
kers potentially have the greatest role in simple detec-
tion of myocyte necrosis, their independent utility in
this setting remains inaccurate.
To increase the diagnosis, the accuracy of delayed en-
hancement CMR imaging (DE-CMR) can quantify re-
versible and irreversible myocyte necrosis.
In fact in recent studies, Pegg et al. [6] reported increased
cardiomyocyte necrosis associated with the hybrid tech-
nique of on-pump beating-heart CABG both detected by
DE-CMR and biomarkers. In this study, the authors had as
an end point the effectiveness of biomarkers troponin I
(TnI) and creatine kinase-MB isoform (CK-MB) and com-
pared these with CMR to diagnose AMI.
Moreover, these authors evaluated the efficacy of car-
diac enzymes for determination of cardiomyocyte necro-
sis after CABG and compared this with the efficacy of
CMR [7].
In the MASS-V study, we will prospectively examine
the incidence and extent of new DE-CMR-defined irre-
versible injury in patients undergoing PCI or CABG and
correlate it with postprocedural changes in TnI and CK-
MB. Our hypothesis is that the releasing of biomarkers
does not necessarily leads to myocardial fibrosis or left
ventricular dysfunction; and the cut-off levels to define
periprocedural AMI would be different from the ones
established in current guidelines.
Methods/Design
The MASS-V Trial is an institutional project that the
Heart Institute (InCor), Hospital das Clinicas, University
of São Paulo designed to prospectively investigate 150
patients with multivessel coronary artery disease (CAD)
with normal left ventricle ejection fraction (LVEF) and
with a formal indication for CABG or PCI. Fifty patients
will be operated on with cardiopulmonary bypass (CPB)
and another 50 patients with the same arterial and
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ventricular conditions and also with a proper indication
for myocardial revascularization will be operated on
without the help of the CPB circuit. Another 50 patients
with CAD and preserved ventricular function with a for-
mal indication for percutaneous coronary intervention
(PCI) with the use of intracoronary "stents” will be
analyzed.
The inclusion criteria will determine which patients are
eligible for which of the three procedures. Anginal symp-
toms must be stable and the LVEF preserved. The main
steps of the procedures are shown in Figure 1. Exclusion
criteria include the following: recent myocardial infarction
(≤6 months); signs of manifest or suspected infections
or rheumatologic disease activity; chronic renal failure
(creatinine level >2.0 mg/dL); recent (≤ 6 months) pul-
monary embolism or venous thromboembolism; not
signing the consent form; contraindication for the use
of glycoprotein IIb/IIIa inhibitors or CMR examination,
for example, a person with a pacemaker or severe
claustrophobia.
All patients will undergo CMR before and after surgi-
cal or percutaneous interventions to determine the pres-
ence or absence of myocardial necrosis complications
after the procedure.
In addition, we will be evaluating the release of cardiac
necrosis markers immediately before and after each pro-
cedure. The measurement of necrosis markers in the
series will be conducted 6, 12, 24, and 36 hours after the
percutaneous intervention. For the surgical procedures,
dosage series will expand from 48 to 72 hours.
CMR protocol
The patients will be studied in a 1.5-T clinical MR scan-
ner (Philips Achieva), and steady-state free-procession
cine images will be acquired in 2 long-axis (2 and 4
chambers view) and 8 to 10 short-axis views of the left
ventricle. A gadolinium-based contrast agent (Gadote-
rate meglumine Gd-DOTA, Guerbet SA, France) will
then be injected intravenously (0.1 mmol per kilogram
of body weight), and contrast-enhanced images will be
acquired after a 5- to 10-minute delay with the use of
an inversion-recovery segmented sequence. Contrast-
enhanced images will be acquired in long- and short-
axis planes identical to the cine images. Typical voxel
size will be 1.6x2.1x8mm, with a reconstruction matrix
of 528 and a reconstructed voxel size of 0.6 mm. The
method for acquiring and analyzing CMR is standar-
dized in our service and is reproduced according to con-
ventional techniques [2,8].
Delayed enhancement
Delayed enhancement of cardiac magnetic resonance
will be performed with a phase-sensitive inversion recov-
ery (PSIR) sequence (repetition time 6.1, echo time
3.0 ms, voxel size 1.6x2.1x8mm, flip angle 25o) following
a 5-min time delay after the administration of 0.1 mmol/
kg contrast agent (Gadoterate meglumine Gd-DOTA,
Guerbet SA, France). Images will be acquired in two
long-axis planes and in a short-axis stack covering the
entire left ventricle. The inversion time will be meticu-
lously adjusted throughout the acquisition to obtain
Figure 1 Algorithm of MASS V Trial. Legend: Enrollment and follow-up procedures in the arms of MASS V trial.
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optimal nulling of remote normal myocardium. The slice
thickness at the apex will be reduced to 5 mm to avoid a
partial volume effect [7].
CMR postprocessing and data analysis
All areas of late gadolinium-DTPA hyperenhancement
will be quantified with a computer-assisted planimetry
program - CMR42 v. (Circle Cardiovascular Imaging,
Calgary, Canada) and interpreted by two experienced
observers blinded to the interventional technique and
biochemical data. When measurements are different, a
third observer will perform a review and a consensus
will be obtained.
Hyperenhanced pixels are defined as those with image
intensities >2 SDs above the mean of image intensities
in a remote myocardial region in the same image. Fur-
thermore, we prospectively identified the site of any new
hyperenhancement in relation to the implanted stent.
Areas of new hyperenhancement that occur in the same
short-axis image as the stent will be classified as adja-
cent to stent injury, whereas new hyperenhancement
that occurs in the myocardium distal to the stent is
deemed downstream injury.
Just as with a percutaneous intervention, hyperen-
hanced pixels will be defined as image intensities greater
than two standard deviations above the mean intensities
in a remote myocardial region in the same image. Prein-
tervention and postintervention scans will be read side
by side in both surgical techniques, with and without
extracorporeal circulation.
Biochemistry
Blood samples will be collected from each patient for
measurement of troponin I (TnI) and CK-MB mass im-
mediately before PCI and 6, 12, 24, and 36 hours after
the procedure. For patients undergoing coronary artery
bypass surgery, on-pump or off-pump, these cardiac
markers will be measured immediately before surgery
and 6, 12, 24, 36, 48, and 72 hours after surgery.
The surgeon and clinical team will be blinded to the
CK-MB or TnI data.
All the samples will be centrifuged at 3000 rpm for
20 minutes and analyzed within 2 hours after specimen
collection. TnI and CK-MB analysis will be performed in
an immunoassay analyzer (ADVIA Centaur, Siemens
Health Care Diagnostics, Tarrytown, NY). According to
the manufacturer, the lower limit of detection of TnI
using a high-sensitivity kit, the Ultra kit, is 0.006 ng/mL,
and the 99th percentile and MI reference limits are re-
spectively 0.04 and 0.76 ng/mL. The assay precision,
represented by the percentage coefficient of variation (%
CV) is ≤ 10 % at 0.03 ng/mL.
The detection limit of the CK-MB mass kit is 0.18 ng/
mL, and the cut off values at the 99th percentile,
established by our laboratory, are 3.8 ng/mL for women
and 4.4 ng/mL for men. The CVs for CK-MB mass, as
specified by the manufacturer, are 3.91 % at 3.55 ng/mL
and 3.61 % at 80.16 ng/Ml.
Statistical analysis
Values will be expressed as mean (±SD) or median
(interquartile range) as appropriate. The paired-sample
t test and the unpaired-sample t test will be used to com-
pare means within the study group or between sub-
groups. χ2 statistics with Fisher’s exact test will be used
for comparison of discrete variables. Continuous vari-
ables that were not distributed normally will be com-
pared with the Mann–Whitney U test, and correlation
between such variables will be made with the Spearman
rank test. Binary logistic regression will be performed to
determine which clinical and angiographic parameters
predict the likelihood of myocardial hyperenhancement.
Multivariate logistical regression will be used to assess
the relative contribution of various clinical and angio-
graphic variables to the presence of new hyperenhance-
ment after PCI or CABG. A probability value of <0.05 is
considered statistically significant.
Trial outcomes
Primary outcome considered is overall death in a 5-year
follow-up. Secondary outcomes are levels of CK-MB iso-
enzyme and I-Troponin in association with presence of
myocardial fibrosis and left ventricle ejection dysfunc-
tion assessed by CMR.
Discussion
The release of biomarkers of myocardial necrosis occurs
in most patients who undergo mechanical interventions
of the heart, both CABG and PCI. Among the causes of
this release are the trauma caused by the handling organ,
contact of blood with the bypass circuit, aortic cross
clamping, and reperfusion injury. On the other hand,
periprocedural myocardial injury during PCI can result
from procedural complications, such as distal embolization,
side-branch occlusion, coronary dissection, and disruption
of collateral flow.
The clinical significance and long-term prognosis of
this condition continues to be debated. Initial short-term
follow-up found no increase in the incidence of cardiac
events; however, further large prospective trials have
suggested that elevation of biomarkers of myocardial ne-
crosis after PCI or CABG is clinically relevant. In
addition, outcomes after CABG or PCI with very high
procedural TnI or CK-MB levels have prognostic impli-
cations considered similar to those of spontaneous acute
myocardial infarction.
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Delayed enhancement CMR imaging can quantify irre-
versible myocyte necrosis for the identification of sube-
docardial infarction.
However, uncertainties remain about the mechanisms
and functional significance of the release of cardiac bio-
markers and the direct relationship between procedure-
related troponin and CK-MB increase and the degree of
myocardial tissue loss.
Ethical considerations
MASS-V trial will be conducted in accordance with the
principles of the Declaration of Helsinki and with laws
and regulations of our country. The Ethics Committee
of the Heart Institute of the University of São Paulo,
Brazil, approved the study protocol. The attending phys-
ician will obtain written informed consent from the all
study participants.
Trial status
This is a proposed trial and the enrollment process has
not started until the date of manuscript submission.
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